Precision Medicine in Head and Neck Cancer

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: closed (20 May 2024) | Viewed by 1399

Special Issue Editor


E-Mail Website
Guest Editor
Santi Paolo e Carlo Hospital, Department of Health Sciences, Università degli Studi di Milano, Milan, Italy
Interests: rhinology; head and neck cancer; pediatric otolaryngology

Special Issue Information

Dear Colleagues,

We cordially invite you to submit your original research and review articles for an upcoming Special Issue of the Journal of Personalized Medicine, focused on "Precision Medicine in Head and Neck Cancer". This Special Issue aims to report on the latest advancements and breakthroughs in the field, highlighting innovative diagnostic and therapeutic approaches.

Monoclonal antibodies for treating head and neck cancer, as well as applications of artificial intelligence and large language models to assist in cancer diagnosis, treatment, and patient care, are the most widely known developments towards personalized medicine in head and neck oncology. However, these are just a few examples, and we welcome a diverse range of topics related to personalized medicine in head and neck cancer.

We look forward to receiving your valuable contributions to this Special Issue and to advancing our collective understanding of personalized medicine in head and neck cancer.

Best regards,

Dr. Alberto Maria Saibene
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized medicine
  • head and neck cancer
  • monoclonal antibodies
  • cancer diagnosis
  • cancer treatment
  • artificial intelligence
  • large language models
  • cancer patient care
  • biomarkers
  • targeted therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

11 pages, 424 KiB  
Systematic Review
Intraoperative Neuromonitoring Does Not Reduce the Risk of Temporary and Definitive Recurrent Laryngeal Nerve Damage during Thyroid Surgery: A Systematic Review and Meta-Analysis of Endoscopic Findings from 73,325 Nerves at Risk
by Anna Teresa Cozzi, Alice Ottavi, Paolo Lozza, Alberto Maccari, Roberto Borloni, Letizia Nitro, Elena Giulia Felisati, Andrea Alliata, Barbara Martino, Giancarlo Cacioppo, Manuela Fuccillo, Cecilia Rosso, Carlotta Pipolo, Giovanni Felisati, Loredana De Pasquale and Alberto Maria Saibene
J. Pers. Med. 2023, 13(10), 1429; https://doi.org/10.3390/jpm13101429 - 23 Sep 2023
Cited by 1 | Viewed by 1169
Abstract
Background: While intraoperative neuromonitoring (IONM) helps the early identification of recurrent laryngeal nerve (RLN) damage, IONM’s role in RLN damage prevention is not defined, given the lack of large studies on the subject. Methods: In a PRISMA-compliant framework, all original thyroid surgery prospective [...] Read more.
Background: While intraoperative neuromonitoring (IONM) helps the early identification of recurrent laryngeal nerve (RLN) damage, IONM’s role in RLN damage prevention is not defined, given the lack of large studies on the subject. Methods: In a PRISMA-compliant framework, all original thyroid surgery prospective studies providing early postoperative endoscopic data for all patients were pooled in a random-effects meta-analysis. We compared the temporary (and definitive where available) RLN damage rates according to IONM use and IONM type (intermittent, I-IONM, or continuous, C-IONM). Results: We identified 2358 temporary and 257 definitive RLN injuries in, respectively, 73,325 and 66,476 nerves at risk. The pooled temporary and definitive RLN injury rates were, respectively, 3.15% and 0.422% considering all procedures, 3.29% and 0.409% in cases using IONM, and 3.16% and 0.463 in cases not using IONM. I-IONM and C-IONM, respectively, showed a pooled temporary RLN injury rate of 2.48% and 2.913% and a pooled definitive injury rate of 0.395% and 0.4%. All pooled rates had largely overlapping 95% confidence intervals. Conclusions: Our data suggest that IONM does not affect the temporary or definitive RLN injury rate following thyroidectomy, though its use can be advised in selected cases and for bilateral palsy prevention. Full article
(This article belongs to the Special Issue Precision Medicine in Head and Neck Cancer)
Show Figures

Figure 1

Back to TopTop